公司概述
NRx Pharmaceuticals, Inc. operates as a clinical-stage bio-pharmaceutical enterprise dedicated to the development of novel therapeutics aimed at treating central nervous system disorders, specifically targeting conditions such as suicidal depression, post-traumatic stress disorder, and chronic pain. The company functions within the healthcare sector and the biotechnology industry, positioning itself as an early-stage innovator focused on advancing drug candidates like NRX-101 through clinical development phases. In terms of scale, NRx Pharmaceuticals maintains a market capitalization of $73.74 million, reports total annual revenue of $1.23 million, and employs a workforce of 29 individuals. These financial metrics indicate that the company possesses a relatively small market valuation and limited revenue generation relative to its peers, reflecting its status as a pre-revenue or early-revenue biotechnology firm where significant capital expenditure is typically directed toward research and development rather than commercial sales.
财务健康
The company reported a revenue of $1.23 million over the trailing twelve months, accompanied by a net income of -$28,622,000 and an EBITDA of -$16,118,000. The substantial disparity between the modest revenue figure and the significant net loss reveals a cost structure heavily weighted toward operating expenses, which is characteristic of clinical-stage biotechnology companies investing heavily in R&D and clinical trial costs before generating substantial commercial income. Free cash flow stands at -$805,875, indicating that the company is currently burning cash to fuel its development pipeline, which limits immediate financial flexibility but is a standard operational reality for entities in the clinical development phase. The gross margin is recorded at 58.8%, while the operating margin is -467.3% and the profit margin is 0.0%; the positive gross margin suggests efficient production or supply chain costs relative to sales, whereas the deeply negative operating margin underscores the high overhead and development costs consuming the entire operating income. Regarding capital structure, the company holds $7.80 million in cash against $631,000 in debt, with a debt-to-equity ratio listed as N/A, suggesting a balance sheet that is primarily funded by equity and cash reserves rather than leveraged debt. However, the current ratio of 0.31 indicates that current liabilities exceed current assets, signaling potential short-term liquidity constraints that require careful management of cash burn and potential financing events. Return on Equity is N/A due to the capitalization structure and losses, while Return on Assets stands at -121.8%, reflecting that the company's asset base is currently generating negative returns as it accumulates intangible assets and incurs development costs.
估值评估
The trailing twelve-month P/E ratio is N/A, whereas the forward P/E is 17.15, a divergence that implies the market expects the company's earnings to improve significantly in the future, potentially transitioning from losses to profitability as clinical trials advance and commercialization begins. The price-to-book ratio is -4.43, a negative figure that typically arises in biotechnology firms with substantial intangible assets or accumulated losses on their balance sheets, indicating that the market valuation does not correlate directly with the traditional book value of tangible assets. The price-to-sales ratio is 60.20, and the EV/EBITDA is -4.13; these alternative valuation metrics suggest that the market is pricing the stock based on growth potential and pipeline value rather than current profitability, as the high P/S multiple reflects expectations of future revenue expansion despite current lack of earnings. The 52-week high is $3.84 and the 52-week low is $1.62, providing a trading range within which the stock has fluctuated over the past year, though the specific current trading price relative to this exact range is not provided in the available data points. The beta value is 1.83, which indicates that the stock price is significantly more volatile than the broader market, moving with much greater intensity than the general equity index, a common characteristic for small-cap biotechnology stocks with binary event-driven risk profiles.
Growth & Income
The available data indicates that revenue growth year-over-year and earnings growth year-over-year are both N/A, suggesting that the company has not yet achieved consistent comparable growth rates or has experienced significant fluctuations in its early commercial or revenue-generating stages. Consequently, the company does not currently pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that instead of distributing income to shareholders, the firm retains all earnings and cash flow to reinvest into its research and development pipeline. This reinvestment strategy is typical for clinical-stage companies that prioritize advancing their drug candidates, such as NRX-101, over providing current income to investors. The overall growth and income profile of NRx Pharmaceuticals, Inc. is characterized by a lack of current dividend income and undefined historical growth rates, with the company's value proposition entirely dependent on the successful execution of its clinical development program and future commercialization potential rather than existing financial performance metrics.